HCV ADVOCATE WEEKLY NEWS REVIEW

[Guest guest]

HCV ADVOCATE WEEKLY NEWS REVIEW

Week Ending: November 28, 2009

Backed by House, 6 patients sue Pawlenty, state officials Increasing Long-Term Survival in Patients with Severe Liver Cancer Diet Rich in Processed Food Linked to Increased Risk for Depression My View: Ignoring Prisoners' Health Imperils Community Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C Antiviral Therapy for Hepatitis C Appears To Be Declining in the U.S.; Lack of Diagnosis Is Primary Barrier to Treatment Advanced Hepatitis Drug Nears FDA Approval NVHR: New Data Finding Fewer than 1 in 5 Hepatitis C Patients Receiving Antiviral Therapy is ‘Wake-Up Call’ for Washington to Act Women's Health: Combating a Common Virus Vitamin D Boosts Treatment of Chronic Hepatitis C Human Genome Sciences Submits BLA to FDA for ZALBIN for Chronic Hepatitis C Scientists See Little Difference in Survival Rates between Non-Alcoholic and Alcoholic Liver Transplants Tips for Managing the Flu with Liver Disease Metobolomics Uncovers Key Indicators of Nonalcoholic Fatty Liver Disease New Data Emerges on Liver Transplant Survival Rates Needle Sticks Can Be a Job Hazard for Medical Students Future of Maine's Needle Exchange Programs in Doubt Vibrating Technology Promises to Replace Biopsies in Diagnosing Diseased Tissue Tripep: The ChronVac-C® Study Has Been Successfully Completed with Good Safety and Favorable Clinical Data With Jesper Mattsson

http://www.hcvadvocate.org/news/newsRev/2009/NewsRev-337.html